Comera SPAC Presentation Deck
CLS-001: Addressing Unmet Need in Large Market
First program focuses on formulating a SQ version of a widely-marketed,
successful IV biologic therapy targeting Inflammatory Bowel Disease (IBD)
Program
Therapeutic Area
Development Status
Key Milestone
Competition
Peak Sales Potential
SQ formulation of marketed IV mAb
IBD
Ulcerative colitis and Crohn's disease
month period following approval.
Formulation development
IND filing: Q1 2024
No SQ in US
$250M-$500M base case
Global Revenue ($B)
30
25
19.2
20
15
10
5
20.1
0
21.0
Global IB Market*
Revenue in billions (USD)
21.9
22.9
Year
Source: https://www.grandview research.com/industry-analysis/inflammatory-bowel-disease-ibd-treatment-market; https://www.marketwatch.com/press-release/inflammatory-bowel-disease-ibd-treatment-
(•)<)
market-analysis-share-trends-size-forecast-from-2020---2030-2021-11-01?tesla-y; https://www.yahoo.com/now/global-inflammatory-bowel-disease-treatment-103800897.html;
https://qualiketresearch.com/reports-details/Inflammatory-Bowel-Disease-Treatment-Market; Al-Horani et., al., Nat Rev Drug Disc (21):2022; Peak sales potential reflects maximum estimated sales in a 12-
Comera
23.9
25.0
LIFE SCIENCES
2020 2021 2022 2023 2024 2025 2026 2027 2028
26.1
27.3
23View entire presentation